Radiotherapy
The Role of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Thoracic Tumors
Cancers 2024 July 11 [Link] Federica Danuzzo, Maria Chiara Sibilia, Sara Vaquer, Andrea Cara, Enrico Mario Cassina, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Antonio Tuoro, Francesco Petrella Abstract Pleural mesothelioma (PM) is a rare but aggressive thoracic tumor with a poor prognosis. Multimodal treatment-including induction chemotherapy, aggressive surgical resection, radiotherapy and immunotherapy in selected cases-currently…
Read MoreExtensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT
World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…
Read MoreClinical outcomes of stereotactic body radiation therapy for malignant pleural mesothelioma
Radiotherapy and Oncology 2023 December 15 [Link] Jacob Y Shin, Michael Offin, Charles B Simone, Zhigang Zhang, Annemarie F Shepherd, Abraham J Wu, Narek Shaverdian, Daphna Y Gelblum, Daniel R Gomez, Jennifer L Sauter, Michelle S Ginsberg, Prasad S Adusumilli, Valerie W Rusch, Marjorie G Zauderer, Andreas Rimner Abstract Background: The objective of this study…
Read MoreA deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
Translational Cancer Research 2023 October 31 [Link] Wei Li, Minghang Zhang, Siyu Cai, Siqi Li, Biao Yang, Shijie Zhou, Yuanming Pan, Shaofa Xu Abstract Background: Malignant pleural mesothelioma (MPM) is a rare disease with limited treatment and poor prognosis, and a precise and reliable means to predicting MPM remains lacking for clinical use. Methods: In…
Read MoreMesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma
Biochemical Pharmacology 2023 August [Link] Valentina Coccè, Mara Bonelli, Silvia La Monica, Roberta Alfieri, Luisa Doneda, Eleonora Martegani, Giulio Alessandri, Costanza Annamaria Lagrasta, Aldo Giannì, Valeria Sordi, Francesco Petrella, Leda Roncoroni, Francesca Paino, Augusto Pessina Abstract Malignant pleural mesothelioma is an asbestos-related tumor originating in mesothelial cells of the pleura that poorly responds to chemotherapeutic…
Read MoreIndividualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma
Cancer Medicine 2023 April 19 [Link] Yang Wo, Yizhou Peng, Zhigang Wu, Pengcheng Liu, Yan Shang, Xuxia Shen, Yihua Sun Abstract Objectives: The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized…
Read MoreOne Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreMalignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)
Cancers 2023 February 7 [Link] Elisabetta Parisi, Donatella Arpa, Giulia Ghigi, Lucia Fabbri, Flavia Foca, Luca Tontini, Elisa Neri, Martina Pieri, Simona Cima, Marco Angelo Burgio, Maria Luisa Belli, Luca Luzzi, Antonino Romeo Abstract Malignant Pleural Mesothelioma (MPM) is a rare malignancy with an overall poor prognosis. The standard therapeutic strategy in early-stage disease is…
Read MoreImportance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma
The Thoracic and Cardiovascular Surgeon 2023 February 3 [Link] İlteriş Türk, Gokturk Findik, Mehmet Çetin, Pinar Bicakcioglu, Selim Şakir Erkmen Gülhan, Koray Aydoğdu, Ülkü Yılmaz, Funda Demirağ Abstract Background: Complexities in TNM staging in epithelioid malignant pleural mesothelioma (MPM) may lead to errors in treatment selection, leading to major surgical interventions in patients with low…
Read MoreUnusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports
Case Reports in Oncology 2022 November 8 [Link] Dominik Neff, Barbara-Christina Padberg Sgier, Hannah Dietze, Joachim Müller, Martin Früh Abstract Malignant peritoneal mesothelioma is a rare disease. Patients mainly present with abdominal distension, pain, nausea, and weight loss with or without an exposure history of asbestos. Diagnosis may be difficult from a clinical and histopathologic…
Read More